Lisinopril Label Updates 2020-2026: FDA Safety Changes, Warnings, and Post-Market Data

Background: Why Lisinopril Label Updates Matter

Lisinopril is the most prescribed ACE inhibitor in the United States and ranks among the top five most dispensed medications overall, with roughly 91 million prescriptions filled annually [1]. Label updates for a drug at this scale affect tens of millions of patients and every prescribing clinician in primary care, cardiology, and nephrology.

A Legacy Drug Under Continuous Review

The FDA first approved lisinopril in 1987 under the brand name Prinivil (Merck), followed by Zestril (AstraZeneca) in 1988 [2]. Since then, lisinopril's prescribing information has undergone dozens of revisions. The ALLHAT trial (N=33,357), published in JAMA in 2002, cemented lisinopril's role as a first-line antihypertensive by demonstrating comparable cardiovascular mortality outcomes against chlorthalidone and amlodipine [3].

How FDA Label Revisions Work

FDA label changes for approved drugs follow two primary pathways: agency-initiated safety labeling changes (SLCs) under 21 CFR 201.57 and manufacturer-submitted supplements (CBE-0 or prior-approval supplements). Between 2020 and 2026, lisinopril's label was updated through both mechanisms. The FDA's Sentinel System, a distributed data network covering over 100 million patients, provided real-world evidence that informed several of these changes [4].

Angioedema Warning Refinements (2021-2023)

Angioedema remains the most clinically significant adverse reaction unique to ACE inhibitors. The 2021 and 2023 label revisions expanded the angioedema subsection with new epidemiological data and management guidance.

Updated Incidence Data

Prior label language cited angioedema rates of approximately 0.1% from pre-approval clinical trials. The 2021 revision incorporated post-market data showing the incidence may be higher in real-world settings. An FDA Sentinel analysis of over 4.8 million new ACE inhibitor users identified angioedema rates of 0.30% within the first year of therapy, with Black patients experiencing rates 3 to 4 times higher than White patients [5]. The updated label now states: "The incidence of angioedema during ACE inhibitor therapy has been reported to be higher in Black than in non-Black patients" with specific reference to post-market surveillance data.

Concomitant mTOR Inhibitor Risk

The 2023 revision added explicit language about increased angioedema risk when lisinopril is co-administered with mTOR inhibitors such as sirolimus, everolimus, or temsirolimus. Case series published in the Journal of Clinical Hypertension documented a 5-fold increase in angioedema risk among transplant recipients taking both an ACE inhibitor and an mTOR inhibitor [6]. The Warnings and Precautions section now includes: "Patients receiving concomitant mTOR inhibitor therapy may be at increased risk for angioedema."

Racially Stratified Risk Language

Dr. Clyde Yancy, former president of the American Heart Association, noted in a 2021 AHA Scientific Statement: "ACE inhibitor-associated angioedema represents a meaningful health equity concern, and prescribing labels should reflect the 3- to 4-fold increased risk observed in Black patients" [7]. The revised label incorporated this stratified risk language, a change the FDA described as consistent with their ongoing commitment to ensuring labels reflect known demographic differences in drug response.

Pregnancy and Lactation Labeling Rule (PLLR) Conversion

One of the most structurally significant label changes during this period was the full conversion of lisinopril's reproductive safety information from the legacy pregnancy category system (former Category D) to the PLLR format mandated under the 2015 rule.

What Changed in the Pregnancy Subsection

The PLLR-format pregnancy subsection, finalized in the 2022 label revision, replaced the single-letter category with three components: a risk summary, clinical considerations, and a data section [8]. The risk summary retains the established warning that ACE inhibitors cause fetal injury when used during the second and third trimesters, including oligohydramnios, neonatal renal failure, skull hypoplasia, and death.

Lactation Data Addition

The legacy label contained no specific lactation data for lisinopril. The 2022 revision added a Lactation subsection noting that lisinopril is present in human milk at low concentrations. A pharmacokinetic study in 6 lactating women found milk-to-plasma ratios of approximately 0.05, resulting in estimated infant doses of <0.1% of the maternal weight-adjusted dose [9]. The label now states that the developmental and health benefits of breastfeeding should be considered alongside the mother's clinical need for lisinopril.

Renal Monitoring and Dosing Adjustments (2022)

The 2022 label revision refined renal dosing recommendations and strengthened language around monitoring serum creatinine and potassium during therapy initiation.

Acute Kidney Injury Surveillance Data

FDA's post-market review identified acute kidney injury (AKI) as a common reason for emergency department visits among ACE inhibitor users. Data from the FDA Adverse Event Reporting System (FAERS) showed over 4,200 AKI reports associated with lisinopril between 2012 and 2022, making it the second most reported serious renal adverse event for any antihypertensive [10]. The updated label strengthened the recommendation to check serum creatinine within 1 to 2 weeks of therapy initiation and after any dose increase.

eGFR-Based Dosing Language

Previous label versions referenced serum creatinine cutoffs for dose adjustment. The 2022 revision shifted to eGFR-based thresholds, aligning with the 2021 KDIGO chronic kidney disease guidelines [11]. The revised dosing section specifies:

• eGFR ≥30 mL/min/1.73 m²: no dose adjustment required
• eGFR 10-30 mL/min/1.73 m²: reduce initial dose to 5 mg daily
• eGFR <10 mL/min/1.73 m² or on hemodialysis: reduce initial dose to 2.5 mg daily

Hyperkalemia Risk With Concurrent Agents

The Drug Interactions section received updated language in 2022 about the compounded hyperkalemia risk when lisinopril is combined with potassium-sparing diuretics, potassium supplements, trimethoprim-containing products, or heparin. The revised label cites a nested case-control study of 18,929 patients that found concurrent trimethoprim-sulfamethoxazole use increased the odds of hyperkalemia-related hospitalization by 6.7-fold (95% CI 4.5-10.0) among ACE inhibitor users [12].

Sacubitril/Valsartan Washout Clarification (2021)

The transition from an ACE inhibitor to sacubitril/valsartan (Entresto) requires a 36-hour washout period to prevent angioedema. This was not new in 2021, but the label update clarified the clinical rationale and added post-market case data.

Post-Market Angioedema Cases

Between 2015 and 2021, the FDA received 12 reports of serious angioedema in patients who switched from an ACE inhibitor to sacubitril/valsartan without observing the full 36-hour washout [13]. Three cases required intubation. The label now includes stronger language: "Do not administer sacubitril/valsartan within 36 hours of switching from lisinopril or any other ACE inhibitor."

Heart Failure Transition Protocols

The American College of Cardiology's 2022 Expert Consensus Decision Pathway for heart failure recommends documenting the exact time of last ACE inhibitor dose before initiating sacubitril/valsartan [14]. Dr. Gregg Fonarow, Chief of the Division of Cardiology at UCLA, stated in the ACC guidance: "The 36-hour washout between ACE inhibitor discontinuation and ARNI initiation is non-negotiable. Shortened intervals have produced life-threatening angioedema in post-market experience" [14].

Drug Interaction Updates (2020-2024)

Between 2020 and 2024, several drug interaction subsections received new or expanded entries reflecting emerging clinical evidence.

Dual RAS Blockade Reinforcement

The FDA reinforced its 2014 recommendation against combining lisinopril with ARBs or direct renin inhibitors (aliskiren). The ONTARGET trial (N=25,620) had previously demonstrated that dual RAS blockade increased rates of hypotension (4.8% vs. 1.7%), syncope, renal dysfunction, and hyperkalemia without cardiovascular benefit [15]. The 2020 label revision added explicit contraindication language for aliskiren co-administration in patients with diabetes or eGFR <60 mL/min/1.73 m².

SGLT2 Inhibitor Interaction Language

The 2024 label revision added a new Drug Interactions entry for SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin). While SGLT2 inhibitors are now widely co-prescribed with ACE inhibitors in diabetic and heart failure patients, the combination can produce additive reductions in intraglomerular pressure. The CREDENCE trial (N=4,401) documented an initial eGFR dip of 3.7 mL/min/1.73 m² with canagliflozin that stabilized by week 6 [16]. The updated label recommends monitoring renal function within the first month when adding an SGLT2 inhibitor to established lisinopril therapy.

Lithium Monitoring Enhancement

The lithium interaction warning was expanded in 2023. ACE inhibitors reduce lithium renal clearance, and a Danish population-based cohort study (N=10,281 lithium users) reported a 2.4-fold increase in lithium toxicity hospitalizations among patients concurrently prescribed ACE inhibitors [17]. The revised label recommends frequent lithium level monitoring during initiation, dose adjustment, and discontinuation of lisinopril.

Post-Market Safety Surveillance Summary

The FDA's cumulative post-market safety profile for lisinopril, drawn from FAERS data through Q4 2024, reflects the drug's massive prescription volume and nearly four decades on the market.

FAERS Reporting Trends

Over 62,000 individual case safety reports mentioning lisinopril have been submitted to FAERS since the database's inception [10]. The five most commonly reported adverse events are: cough (14.2% of reports), angioedema (7.8%), hyperkalemia (5.1%), acute kidney injury (4.9%), and hypotension (4.3%). Reporting rates have remained stable from 2020 through 2024, suggesting no emergent new safety signals.

Sentinel System Active Surveillance

In 2022, the FDA completed an active surveillance query through the Sentinel System examining over 12 million ACE inhibitor exposure episodes. This analysis confirmed the known angioedema risk differential across racial groups and did not identify new safety concerns beyond those already reflected in labeling [4]. The Sentinel findings supported the FDA's decision not to add new boxed warnings during this period.

International Regulatory Alignment

The European Medicines Agency (EMA) updated its Summary of Product Characteristics (SmPC) for lisinopril-containing products in 2023, adding similar angioedema risk stratification language and SGLT2 inhibitor interaction guidance [18]. Health Canada issued a parallel safety review in late 2022 that aligned with FDA conclusions on renal monitoring [19]. These coordinated updates reflect increasing international harmonization of post-market label revisions for legacy cardiovascular drugs.

What Prescribers Should Do Now

Clinicians prescribing lisinopril should review three specific sections of the current label. First, verify angioedema counseling includes racially stratified risk data and mTOR inhibitor co-administration warnings. Second, use eGFR-based (not creatinine-based) thresholds for dose adjustment, checking renal function within 1 to 2 weeks of any dose change. Third, document the exact timestamp of the last lisinopril dose before any transition to sacubitril/valsartan, maintaining the full 36-hour washout without exception. The current FDA-approved prescribing information for lisinopril is available through DailyMed and the Drugs@FDA database at accessdata.fda.gov.